739 results on '"Bertilsson L"'
Search Results
102. Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19
103. Stereospecific analysis of omeprazole supports artemisinin as a potentinducer of CYP2C19.
104. Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype.
105. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6-genes.
106. Ten percent of North Spanish subjects carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.
107. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
108. CYP3A4 and 3A5 catalysed alprazolam metabolism in vitro and in vivo
109. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
110. Multigenic Control of Drug Response and Regulatory Decision-Making in Pharmacogenomics: The Need for an Upper-Bound Estimate of Genetic Contributions
111. Artemisinin induces omeprazole metabolism in human beings
112. Artemisinin induces omeprazole metabolism in human beings.
113. Adsorption of dimethyl methylphosphonate on self-assembled alkanethiolate monolayers
114. Disposition of placentally transferred carbamazepine (Tegretol®) in the newborn
115. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
116. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P 450 CYP1A2 and CYP2C19 hydroxylate melatonin
117. Suicide attempts and impulse control disorder are related to low cerebrospinalfluid 5‐HIAA in mentally disorderedviolent offenders
118. The roles of cytochrome P450 3A4 and lA2 in the 3-hydroxylation of quinine in vivo
119. Inhibition of CYP3A4 does not influence Aromasin® (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV)
120. The effect of omeprazole on intragastric pH and gastrin levels is determined by the CYP2C19 polymorphism more than by H. pylori infection in patients with acid related disease
121. P.1.034 In vivo study in humans on disposition of the enantiomers and metabolites of mirtazapine
122. Molecular interaction of DMMP and water vapor with mixed self-assembled monolayers studied by IR spectroscopy and SAW devices
123. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19.
124. Pharmacogenetics in clinical pharmacology and toxicology
125. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
126. Interethnic Differences in Omeprazole Metabolism in the Two S-Mephenytoin Hydroxylation Phenotypes Studied in Caucasians and Orientals
127. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
128. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
129. Quinidine inhibition of debrisoquine S( + )-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes
130. Infrared study of thiol monolayer assemblies on gold: preparation, characterization, and functionalization of mixed monolayers
131. Relationship between personality and debrisoquine hydroxylation capacity
132. INTERETHNIC DIFFERENCES IN DRUG OXIDATION. IMPLICATIONS FOR THE UTILIZATION OF ANTIDEPRESSANTS AND NEUROLEPTICS
133. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure -- an impact similar to male gender or smoking in schizophrenic patients.
134. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans
135. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI)
136. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
137. Carbamazepine-10,11-Epoxide in Epilepsy A Pilot Study
138. Interaction of Carbamazepine‐10,11‐Epoxide, an Active Metabolite of Carbamazepine, with Valproate: A Pharmacokinetic Study
139. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
140. Importance of genetic factors in the regulation of diazepam metabolism
141. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects – an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.
142. The action of fenfluramine and p-chloramphetamine on serotonergic mechanisms: A comparative study in rat brain nuclei.
143. Little anticholinergic effect of E-10-hydroxynortriptyline compared with nortriptyline in healthy subjects.
144. Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects.
145. Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation.
146. Nortriptyline formation after single oral and intramuscular doses of amitriptyline.
147. E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation.
148. Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.
149. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients-relationship to the debrisoquine hydroxylation metabolic ratio.
150. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.